Microdosing Protocols in 2026: Fadiman, Stamets, and the Clinical Data

What Microdosing Actually Means

Microdosing refers to taking a sub-perceptual dose of a psychedelic substance, typically psilocybin, at a level low enough that it does not produce hallucinations or significantly impair daily functioning. For dried psilocybin mushrooms, that usually falls somewhere between 0.05 and 0.3 grams, depending on the individual and the specific mushroom variety. The aim is to access some of the compound’s neurobiological effects, such as changes in mood, cognition, or emotional flexibility, without the disruption of a full psychedelic experience.

The practice is not new. What is new is the growing body of structured research trying to determine whether the reported benefits hold up under controlled conditions. In 2026, that conversation is maturing, and the findings are nuanced enough to be worth unpacking carefully.

The Fadiman Protocol: Structure and Rationale

Dr. James Fadiman, a psychologist who began documenting self-reports on microdosing decades before it entered mainstream conversation, developed what has become the most referenced psilocybin microdosing schedule in use today. The structure is straightforward: one day on, followed by two days off, repeating in a continuous cycle. Day one is the microdose. Day two is an observation day, allowing the user to notice any residual effects. Day three returns to baseline before the next dose.

Fadiman typically recommends following this cycle for four to eight weeks, then taking a two-to-four-week break. The rationale is tolerance management. Psilocybin acts primarily on serotonin 5-HT2A receptors, and daily dosing causes those receptors to downregulate quickly, blunting any effect. The two rest days are not arbitrary; they are designed to allow receptor sensitivity to recover before the next microdose.

The Fadiman protocol microdosing schedule was refined through thousands of self-reports collected informally over many years. That citizen science approach generated genuinely useful patterns, but it also carries real limitations. Participants were self-selected, doses were self-reported and unverified, and there was no placebo control. These are not reasons to dismiss the data, but they are reasons to hold the conclusions loosely until controlled trials can test the same questions more rigorously.

The Stamets Stack: A Different Philosophy

Mycologist Paul Stamets proposed a different approach, one that goes beyond schedule adjustments and incorporates additional compounds. The Stamets Stack combines a psilocybin microdose (typically 0.1 to 0.2 grams of dried mushroom) with lion’s mane mushroom extract and niacin (vitamin B3), taken on a schedule of four or five days on, followed by two or three days off.

The reasoning behind each component is distinct. Psilocybin, even at sub-perceptual doses, appears to promote neuroplasticity and the formation of new neural connections, a process linked to its serotonergic activity. Lion’s mane contains compounds called hericenones and erinacines, which have shown in preclinical research to stimulate nerve growth factor (NGF) production, supporting neurogenesis. Niacin causes temporary vasodilation, a brief widening of blood vessels throughout the body and brain, which Stamets theorizes helps deliver the other compounds more effectively to neural tissue.

It is a compelling hypothesis. Whether the three components work synergistically in humans the way the theory suggests is a separate question, and the honest answer is that we do not yet have robust controlled trial data specifically testing the full stack as a combination.

What the Research Actually Shows

The most significant published study on psilocybin microdosing to date used an observational design. Rootman and colleagues, including Paul Stamets as a co-author, followed 953 psilocybin microdosers and 180 non-microdosing comparators over approximately 30 days. Published in Scientific Reports in 2022, the study found small to medium improvements in mood and mental health among microdosers, consistent across gender, age, and the presence of existing mental health concerns. Older adults in the microdosing group also showed measurable improvements in psychomotor performance, specifically fine motor speed.

On the Stamets Stack specifically, the study’s supplementary analyses found that adding lion’s mane and niacin to psilocybin did not produce significantly different changes in mood or mental health compared to psilocybin alone, with one notable exception: the combination appeared to have a stronger positive effect on psychomotor performance in older adults. That is an interesting finding, but it comes from observational data and should not be extrapolated too far.

More recent work has begun to introduce stricter controls. A 2025 review of placebo-controlled microdosing trials identified 19 studies and found that microdosing with LSD and psilocybin did produce measurable changes in neurobiology, affect, and cognition relative to placebo. The same review was careful to note that the number of controlled studies remains small, sample sizes are limited, and several design challenges make it difficult to draw firm conclusions. In particular, expectancy effects are difficult to isolate: people who believe they are microdosing often report benefits regardless of whether they received an active compound or a placebo.

A Phase II trial published in BJPsych Open in early 2026 is among the most methodologically rigorous yet designed specifically for psilocybin microdosing. The trial, registered at ClinicalTrials.gov (NCT05259943), is randomizing adults with major depressive disorder to weekly doses of 2 mg psilocybin or placebo over four weeks, with an open-label extension phase and follow-ups extending up to two years. It is measuring not just depression symptoms but also attention, creativity, mindfulness, and quality of life. Results from the experimental phase are forthcoming, and they will offer genuinely useful data on whether a structured psilocybin microdosing schedule can outperform placebo in a clinical population.

A separate line of research published in February 2026 in Neuropharmacology examined creativity specifically, using three double-blind placebo-controlled trials. The findings were selective: active microdosing increased the quality of divergent thinking (the ability to generate original ideas), but did not affect convergent thinking or other divergent-thinking measures. The authors noted the importance of controlling for placebo effects and prior psychedelic experience when interpreting these kinds of results.

Placebo, Expectancy, and Why This Matters

One of the most persistent challenges in microdosing research is that belief in the treatment produces measurable effects on its own. A widely cited self-blinding citizen science study found that both placebo and active microdose groups improved significantly over a four-week period, with no statistically significant difference between them. This does not mean microdosing does nothing; it means the field has not yet clearly separated the pharmacological signal from the expectancy effect in human trials.

This is where the current microdosing clinical trial landscape in 2026 becomes especially important. As larger, better-designed studies begin publishing results, the field will either confirm that psilocybin microdosing produces benefits beyond placebo or it will revise those expectations significantly. Either outcome is useful. What is not useful is treating preliminary findings as settled conclusions.

Who These Protocols Are Designed For

Both the Fadiman protocol and the Stamets Stack were designed with general wellness and cognitive performance in mind, not as clinical treatments for diagnosed conditions. That distinction matters for how you interpret the available data and how you approach the decision to explore microdosing.

People drawn to microdosing often report wanting help with mood regulation, focus, creativity, or tapering off other medications. Some are managing treatment-resistant depression or anxiety. Others are healthy individuals seeking performance enhancement. The research populations studied so far do not consistently map onto any one of these groups, which makes generalizing findings difficult.

What the evidence does suggest is that psilocybin microdosing appears tolerable for most people in the short term, that effects are dose-dependent, and that the quality of the experience (set, setting, and support) influences outcomes in ways that a schedule alone cannot capture. The protocol is a structure. What happens within that structure depends on a great deal more than the dosing calendar.

What to Consider Before Starting

Psilocybin remains a Schedule I substance in the United States, meaning it is federally illegal regardless of protocol or intent. Legal access through regulated programs exists in Oregon and Colorado, and psychedelic therapy research is ongoing at several academic institutions. Outside the US, regulations vary considerably by country. Legal context matters, both for access and for safety, since unregulated supply introduces real uncertainty about dose and purity.

There are also meaningful contraindications. People with personal or family histories of psychotic disorders, bipolar I disorder, or certain cardiac conditions should approach this area with caution and medical consultation. Psilocybin interacts with serotonergic medications, and combining it with SSRIs, SNRIs, or lithium without professional guidance carries real risk. These are not hypothetical concerns.

The protocols discussed here were built on anecdote and citizen science. The emerging clinical trials are beginning to test them more rigorously. Neither of those facts should be minimized. If you are considering microdosing, the clearest thing the research says in 2026 is that doing it with support, honest information, and a framework for integration is safer and more productive than doing it alone.